SCHEMBL2857658

SCHEMBL2857658

COc1ccccc1C(=O)NC(c1ccccc1)C1CCC(NS(=O)(=O)N2CCC(C)CC2)CC1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.55
MEN1 O00255 4/20 0.55
KCNA5 P22460 1/20 0.48
ALDH1A1 P00352 5/20 0.47
HPGD P15428 2/20 0.47
MAPK1 P28482 1/20 0.44
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
MAPT P10636 3/20 0.42
TP53 P04637 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
POLB P06746 1/20 0.42
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
TAS1R2 Q8TE23 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2878387 0.91 KCNA5 (0.46) KMT2AMEN1KCNA5ALDH1A1HPGD
SCHEMBL2854756 0.90 KCNA5 (0.49) KMT2AMEN1KCNA5ALDH1A1HPGD
SCHEMBL2857096 0.90 HPGD (0.48) KMT2AMEN1KCNA5ALDH1A1HPGD
SCHEMBL2867485 0.90 KCNA5 (0.47) KMT2AMEN1KCNA5ALDH1A1HPGD
SCHEMBL2861504 0.89 ALDH1A1 (0.47) KMT2AMEN1KCNA5ALDH1A1HPGD
SCHEMBL2867561 0.86 MAPT (0.52) KMT2AKCNA5ALDH1A1HPGDMAPK1
SCHEMBL2853429 0.86 MAPT (0.44) KMT2AMEN1KCNA5ALDH1A1HPGD
SCHEMBL2858832 0.85 KCNA5 (0.45) KMT2AMEN1KCNA5ALDH1A1HPGD
SCHEMBL5348976 0.84 KCNA5 (0.42) KMT2AMEN1KCNA5ALDH1A1HPGD
SCHEMBL2860891 0.83 KCNA5 (0.44) KMT2AMEN1KCNA5ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2253328-A1 Cycloalkyl inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-11-24 EP disclosed
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2007-06-21 US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed
US-20050234106-A1 Cycloalkyl inhibitors of potassium channel function LLOYD JOHN 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234106-A1 Cycloalkyl inhibitors of potassium channel function KCNJ2, KCNN3, KCNQ5 KMT2A 1396/4885MEN1 4430/4885KCNA5 23/4885
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNN3, KCNQ5 KMT2A 1396/4885MEN1 4430/4885KCNA5 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.